Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID‐19

Авдеев, С. Н.; Moiseev, Sergey; Brovko, Michail; Yavorovskiy, Andrey; Umbetova, Karina; Akulkina, Larisa; Tsareva, Natalya; Merzhoeva, Zamira M.; Гайнитдинова, В. В.; Fоmin, Victоr

doi:10.1111/all.14420

Cited by 67 publications

(71 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A strict screening protocol is needed to identify SARS-CoV-2-infected patients (Figure 4 Patients with controlled asthma are not at higher risk of severe infection than the general population. 52,53 ACE2 expression was shown to be decreased in patients with allergic asthma 54 and in those receiving inhaled corticosteroids. 144 On the other hand, ACE2 expression in asthmatic patients was increased in African Americans and in men, and associated with diabetes, 54 and type 2 inflammation in children is associated with increased expression of TMPRSS2.…”

Section: Should Every Allergic Patient Be Tested For Sars-cov-2 Primentioning

confidence: 97%

“…Allergic airway disease patients appear to be underrepresented among COVID-19 patients. [51][52][53] This could be partly attributed to the low ACE2 expression detected in allergic patients, with or without concomitant asthma. 54 Furthermore, allergen challenge, which induces T-helper (Th) 2 inflammation, 55 has been shown to reduce ACE2 expression in a murine model of asthma, and ACE2 expression was inversely associated with type 2 biomarkers (IL-13, IgE, exhaled nitric oxide fraction).…”

Section: Does Type 2 Airway Inflammation Protect Against Covid-19?mentioning

confidence: 99%

See 1 more Smart Citation

A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2

Riggioni

Comberiati

Giovannini

et al. 2020

Allergy

128

130

View full text Add to dashboard Cite

In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID-19). This disease, caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), has developed into a pandemic. To date, it has resulted in ~9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID-19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence-based medical advice on SARS-CoV-2 and COVID-19. Although the majority of the patients show a very mild, self-limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID-19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a "cytokine storm" leading to acute respiratory distress syndrome, endothelitis, | 2505 RIGGIONI et al.

show abstract

Section: Should Every Allergic Patient Be Tested For Sars-cov-2 Primentioning

confidence: 97%

Section: Does Type 2 Airway Inflammation Protect Against Covid-19?mentioning

confidence: 99%

A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2

Riggioni

Comberiati

Giovannini

et al. 2020

Allergy

128

130

View full text Add to dashboard Cite

show abstract

“…188,190,191 In the line with available reports, experts from 43 countries around the world in ARIA-EAACI statement 186 193 Data are still unclear as the COVID-19 population included in the studies is skewed toward older and hospitalized patients with predisposing comorbidities (such as hypertension, obesity, or diabetes) which are strong confounders. 186,187 Additionally, early clinical reports regarding asthma prevalence among COVID-19 cases often vary in terms of patients' severity including those undergoing home quarantine, 194 hospitalized, 191,195 or referred to intensive care units and requiring mechanical ventilation. 187 As gender, smoking status, ethnicity, lifestyle, genetic background, and asthma phenotype can influence COVID-19 outcomes, these factors should be carefully investigated.…”

Section: Challeng E S In a S Thma Manag Ement During Covid -19 Pandmentioning

confidence: 99%

Advances and recent developments in asthma in 2020

Cevhertas

Öğülür

Maurer

et al. 2020

Allergy

126

View full text Add to dashboard Cite

In this review, we discuss recent publications on asthma and review the studies that have reported on the different aspects of the prevalence, risk factors and prevention, mechanisms, diagnosis, and treatment of asthma. Many risk and protective factors and molecular mechanisms are involved in the development of asthma. Emerging concepts and challenges in implementing the exposome paradigm and its application in allergic diseases and asthma are reviewed, including genetic and epigenetic factors, microbial dysbiosis, and environmental exposure, particularly to indoor and outdoor substances. The most relevant experimental studies further advancing the understanding of molecular and immune mechanisms with potential new targets for the development of therapeutics are discussed. A reliable diagnosis of asthma, disease endotyping, and monitoring its severity are of great importance in the management of asthma. Correct evaluation and management of asthma comorbidity/ multimorbidity, including interaction with asthma phenotypes and its value for the precision medicine approach and validation of predictive biomarkers, are further detailed. Novel approaches and strategies in asthma treatment linked to mechanisms and endotypes of asthma, particularly biologicals, are critically appraised. Finally, due to the recent pandemics and its impact on patient management, we discuss the challenges, relationships, and molecular mechanisms between asthma, allergies, SARS-CoV-2, and COVID-19.

show abstract

“…Однако в настоящее время нет данных о том, что эозинофилы оказывают защитное действие или, наоборот, способствуют поражению легких при SARS-CoV-2 инфекции, хотя эозинопения позволяет предсказать более тяжелое течение заболевания [49]. В нашей когорте абсолютное число эозинофилов в крови было ниже 0,02 × 10 9 /л у большинства больных, госпитализированных в ОРИТ, а случаев эозинофилии крови мы не зарегистрировали [50].…”

Section: материал и методыunclassified

Clinical outcomes of patients with COVID-19 admitted for respiratory support to the intensive care units in Russia

Глыбочко¹,

Fоmin²,

Moiseev³

et al. 2020

CPT

View full text Add to dashboard Cite

Цель. Изучение летальности и факторов риска смерти больных с COVID-19, госпитализированных для респираторной поддержки в отделения реанимации и интенсивной терапии (ОРИТ) лечебных учреждений Российской Федерации. Материал и методы. Ретроспективное исследование было выполнено в Федеральном дистанционном консультативном центре анестезиологии и реаниматологии для взрослых пациентов с COVID-19 на базе Первого МГМУ им. И.М. Сеченова. В исследование включали всех пациентов с известными исходами (смерть от любых причин или выздоровление) SARS-CoV-2 пневмонии, осложнившейся острым респираторным дистресс синдромом (ОРДС), которые были проконсультированы с 16 марта по 3 мая 2020 г. Факторы риска смерти анализировали с помощью многофакторной регрессионной модели Кокса. Результаты. В исследование были включены 1522 пациента, 864 (56,8%) мужчины и 658 (43,2%) женщин. Медиана возраста-62 года. 922 (60,6%) больных находились в ОРИТ стационаров Москвы и Московской области, 600 (39,4%)-лечебных учреждений в 70 регионах Российской Федерации. У 995 (65,4%) больных диагноз SARS-CoV-2 инфекции был подтвержден с помощью ПЦР. Умерли 995 (65,4%) пациентов, выжили 527 (34,6%). Основными причинами смерти были ОРДС (93,2%), сер

show abstract

Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID‐19

Cited by 67 publications

References 13 publications

A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2

A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2

Advances and recent developments in asthma in 2020

Clinical outcomes of patients with COVID-19 admitted for respiratory support to the intensive care units in Russia

Contact Info

Product

Resources

About